Avidity Biosciences
(NASDAQ:RNA)
$25.52
0.85[3.45%]
At close: Mar 28
$25.52
0[0.00%]
After Hours: 4:00PM EDT
Consensus Rating1
Buy
Highest Price Target1
$71.00
Lowest Price Target1
$20.00
Consensus Price Target1
$41.90

Avidity Biosciences Stock (NASDAQ:RNA), Analyst Ratings, Price Targets, Predictions

Avidity Biosciences Inc has a consensus price target of $41.9, established from looking at the 37 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Chardan Capital, and Needham on March 14, 2024, March 5, 2024, and March 4, 2024. With an average price target of $42.67 between Cantor Fitzgerald, Chardan Capital, and Needham, there's an implied 67.19% upside for Avidity Biosciences Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Nov 23
1
Jan
1
Feb
2
Mar
3
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Cantor Fitzgerald
Chardan Capital
Needham
Wells Fargo
Credit Suisse

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Avidity Biosciences

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/14/2024RNABuy Now
Avidity Biosciences
$25.52135.11%Cantor Fitzgerald
Eric Schmidt
→ $60Initiates → OverweightGet Alert
03/05/2024RNABuy Now
Avidity Biosciences
$25.5229.31%Chardan Capital
Keay Nakae
$23 → $33MaintainsBuyGet Alert
03/04/2024RNABuy Now
Avidity Biosciences
$25.5237.15%Needham
Joseph Stringer
→ $35ReiteratesBuy → BuyGet Alert
02/29/2024RNABuy Now
Avidity Biosciences
$25.5237.15%Needham
Joseph Stringer
→ $35ReiteratesBuy → BuyGet Alert
02/29/2024RNABuy Now
Avidity Biosciences
$25.52-9.87%Chardan Capital
Keay Nakae
→ $23ReiteratesBuy → BuyGet Alert
01/03/2024RNABuy Now
Avidity Biosciences
$25.5295.92%Wells Fargo
Yanan Zhu
$50 → $50ReiteratesOverweight → OverweightGet Alert
11/29/2023RNABuy Now
Avidity Biosciences
$25.5237.15%Needham
Joseph Stringer
→ $35ReiteratesBuy → BuyGet Alert
08/09/2023RNABuy Now
Avidity Biosciences
$25.5217.55%Credit Suisse
Judah Frommer
→ $30ReiteratesOutperform → OutperformGet Alert
08/09/2023RNABuy Now
Avidity Biosciences
$25.52-9.87%Chardan Capital
Keay Nakae
$27 → $23MaintainsBuyGet Alert
08/09/2023RNABuy Now
Avidity Biosciences
$25.5237.15%Needham
Joseph Stringer
→ $35ReiteratesBuy → BuyGet Alert
05/22/2023RNABuy Now
Avidity Biosciences
$25.52-21.63%Evercore ISI Group
Josh Schimmer
→ $20UpgradeIn-Line → OutperformGet Alert
05/17/2023RNABuy Now
Avidity Biosciences
$25.5237.15%Needham
Joseph Stringer
→ $35ReiteratesBuy → BuyGet Alert
05/11/2023RNABuy Now
Avidity Biosciences
$25.5295.92%Wells Fargo
Yanan Zhu
$55 → $50MaintainsOverweightGet Alert
05/10/2023RNABuy Now
Avidity Biosciences
$25.5217.55%Credit Suisse
Judah Frommer
→ $30Reiterates → OutperformGet Alert
04/28/2023RNABuy Now
Avidity Biosciences
$25.5237.15%Needham
Joseph Stringer
→ $35Reiterates → BuyGet Alert
03/31/2023RNABuy Now
Avidity Biosciences
$25.5217.55%Credit Suisse
Judah Frommer
$35 → $30MaintainsOutperformGet Alert
03/31/2023RNABuy Now
Avidity Biosciences
$25.52-21.63%Evercore ISI Group
Joshua Schimmer
→ $20DowngradeOutperform → In-LineGet Alert
03/31/2023RNABuy Now
Avidity Biosciences
$25.525.8%Chardan Capital
Keay Nakae
→ $27Reiterates → BuyGet Alert
03/01/2023RNABuy Now
Avidity Biosciences
$25.5237.15%Credit Suisse
Judah Frommer
→ $35Reiterates → OutperformGet Alert

FAQ

Q

What is the target price for Avidity Biosciences (RNA)?

A

The latest price target for Avidity Biosciences (NASDAQ: RNA) was reported by Cantor Fitzgerald on March 14, 2024. The analyst firm set a price target for $60.00 expecting RNA to rise to within 12 months (a possible 135.11% upside). 18 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Avidity Biosciences (RNA)?

A

The latest analyst rating for Avidity Biosciences (NASDAQ: RNA) was provided by Cantor Fitzgerald, and Avidity Biosciences initiated their overweight rating.

Q

When was the last upgrade for Avidity Biosciences (RNA)?

A

The last upgrade for Avidity Biosciences Inc happened on May 22, 2023 when Evercore ISI Group raised their price target to $20. Evercore ISI Group previously had an in-line for Avidity Biosciences Inc.

Q

When was the last downgrade for Avidity Biosciences (RNA)?

A

The last downgrade for Avidity Biosciences Inc happened on March 31, 2023 when Evercore ISI Group changed their price target from N/A to $20 for Avidity Biosciences Inc.

Q

When is the next analyst rating going to be posted or updated for Avidity Biosciences (RNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avidity Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avidity Biosciences was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.

Q

Is the Analyst Rating Avidity Biosciences (RNA) correct?

A

While ratings are subjective and will change, the latest Avidity Biosciences (RNA) rating was a initiated with a price target of $0.00 to $60.00. The current price Avidity Biosciences (RNA) is trading at is $25.52, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch